Your browser doesn't support javascript.
loading
Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.
Moreno, Estefanía; Andradas, Clara; Medrano, Mireia; Caffarel, María M; Pérez-Gómez, Eduardo; Blasco-Benito, Sandra; Gómez-Cañas, María; Pazos, M Ruth; Irving, Andrew J; Lluís, Carme; Canela, Enric I; Fernández-Ruiz, Javier; Guzmán, Manuel; McCormick, Peter J; Sánchez, Cristina.
Affiliation
  • Moreno E; From the Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, the Institute of Biomedicine of the University of Barcelona, 08028 Barcelona, S
  • Andradas C; the Department of Biochemistry and Molecular Biology I, School of Biology and the Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain.
  • Medrano M; From the Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, the Institute of Biomedicine of the University of Barcelona, 08028 Barcelona, S
  • Caffarel MM; the Department of Biochemistry and Molecular Biology I, School of Biology and.
  • Pérez-Gómez E; the Department of Biochemistry and Molecular Biology I, School of Biology and the Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain.
  • Blasco-Benito S; the Department of Biochemistry and Molecular Biology I, School of Biology and the Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain.
  • Gómez-Cañas M; the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, Department of Biochemistry and Molecular Biology III/Instituto Universitario de Investigación en Neuroquímica, School of Medicine, Complutense University, 28040 Madrid, Spain, the Institu
  • Pazos MR; the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, Department of Biochemistry and Molecular Biology III/Instituto Universitario de Investigación en Neuroquímica, School of Medicine, Complutense University, 28040 Madrid, Spain.
  • Irving AJ; the Division of Neuroscience, Ninewells Hospital, University of Dundee, Dundee DD1 9SY, United Kingdom, and.
  • Lluís C; From the Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, the Institute of Biomedicine of the University of Barcelona, 08028 Barcelona, S
  • Canela EI; From the Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, the Institute of Biomedicine of the University of Barcelona, 08028 Barcelona, S
  • Fernández-Ruiz J; the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, Department of Biochemistry and Molecular Biology III/Instituto Universitario de Investigación en Neuroquímica, School of Medicine, Complutense University, 28040 Madrid, Spain, the Institu
  • Guzmán M; the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, the Department of Biochemistry and Molecular Biology I, School of Biology and the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid 28034, Spain.
  • McCormick PJ; From the Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain, the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain, the Institute of Biomedicine of the University of Barcelona, 08028 Barcelona, S
  • Sánchez C; the Department of Biochemistry and Molecular Biology I, School of Biology and the Instituto de Investigación Hospital 12 de Octubre, 28041 Madrid, Spain, cristina.sanchez@quim.ucm.es.
J Biol Chem ; 289(32): 21960-72, 2014 Aug 08.
Article in En | MEDLINE | ID: mdl-24942731
ABSTRACT
The G protein-coupled receptors CB2 (CB2R) and GPR55 are overexpressed in cancer cells and human tumors. Because a modulation of GPR55 activity by cannabinoids has been suggested, we analyzed whether this receptor participates in cannabinoid effects on cancer cells. Here we show that CB2R and GPR55 form heteromers in cancer cells, that these structures possess unique signaling properties, and that modulation of these heteromers can modify the antitumoral activity of cannabinoids in vivo. These findings unveil the existence of previously unknown signaling platforms that help explain the complex behavior of cannabinoids and may constitute new targets for therapeutic intervention in oncology.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, G-Protein-Coupled / Receptor, Cannabinoid, CB2 / Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Biol Chem Year: 2014 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, G-Protein-Coupled / Receptor, Cannabinoid, CB2 / Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans / Male Language: En Journal: J Biol Chem Year: 2014 Type: Article